more_reports

The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics, with a type 1 diabetes cell therapy trial planned for early 2027. Find out why one analyst says Sernova found the right partner.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / PharmaceuticalsMedical DevicesHealthcare Services

Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August

  ()
Rocket Doctor AI reports 3,625 completed U.S. patient visits in the first two months of Q3 2026. The update highlights ongoing U.S. expansion and telehealth momentum for retail investors.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

US Patient Visits Reach 93% of Prior Quarter's Total in Two Months

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported 3,625 completed U.S. patient visits in July and August, alongside 1,555 clinical hours as its U.S. operations expanded.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

AI Cancer Drug Pipeline Advances as 72% of Budget Shifts to Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) cut its Q2 net loss 41% year over year while advancing three AI-powered cancer drug programs and closing a CA$1.99 million non-brokered private placement after quarter-end.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

  ()
Rakovina Therapeutics allocated 72% of its budget to AI-powered drug discovery in the second quarter of 2026, up from 57% in Q2 2025. See the three AI-supported DDR programs and upcoming milestones for retail investors.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43%

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Telehealth Platform Delivers 196% U.S. Visit Growth in Q2

  ()
Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Rocket Doctor AI Signs Strategic Network Agreement to Expand California Reimbursement Access

  ()
New multi-channel partnership opens contracted entry points into workers' compensation, auto medical, and Medicare networks, further extending Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) U.S. partnering strategy.
Tags: Life Sciences Tools & DiagnosticsArtificial Intelligence

Rocket Doctor AI Secures California Network Deal Reaching 60M Consumers

  ()
Rocket Doctor AI enters a major provider network agreement in California covering 60 million consumers across multiple lines including workers compensation and Medicare. Learn the key details and next steps for investors.
Tags: Life Sciences Tools & DiagnosticsArtificial Intelligence

Clinical AI Use Surges as Revenue Climbs and Doctors Embrace New Tools

  ()
Doximity Inc. (DOCS:NYSE) reported 7% revenue growth as workflow active prescribers increased more than 30% year over year and AI Search queries climbed more than 25% quarter over quarter.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

Doximity AI Tools Fuel Physician Engagement Growth Amid Healthcare Digital Shift

  ()
Doximity reports fiscal Q1 revenue of $156.6 million with strong workflow growth. See how its AI suite and 85% physician reach position the company in expanding digital health markets.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

AI Cancer Drug Developer Advances Pipeline as Funding Expands

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing in vivo testing and AI-driven lead optimization across its cancer drug pipeline as it expands relationships with AI companies and pursues additional non-dilutive funding.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review

  ()
GRAIL Inc. (GRAL:NASDAQ) announces that an FDA committee will meet in September to evaluate the Premarket Approval (PMA) application for the Galleri multi-cancer early detection (MCED) blood test. Read why one financial expert thinks it will gain approval.
Tags: Life Sciences Tools & Diagnostics

GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review

  ()
GRAIL Inc. prepares for its Sept. 23 FDA advisory committee meeting on the Galleri MCED test PMA, backed by large clinical studies and growing commercial revenue in the expanding multi-cancer early detection market.
Tags: Life Sciences Tools & Diagnostics

DarioHealth Reports Q2 Revenue, with 62% Gross Margin as AI Platform Expands

  ()
DarioHealth Corp. (DRIO:NASDAQ) reported US$5.2 million in Q2 revenue, a 62% gross margin and US$13.1 million in contracted and late-stage ARR.
Tags: Life Sciences Tools & Diagnostics

AI Chronic Care Platform Adds Fifth Fortune 50 Client, Lifts Margin to 62%

  ()
DarioHealth reported Q2 revenue of $5.2 million with gross margin rising to 62 percent and contracted ARR reaching $13.1 million after signing a fifth Fortune 50 client and expanding provider-backed care.
Tags: Life Sciences Tools & Diagnostics

This AI Healthcare Platform Is Taking Its New York Expansion Through 2029

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its EngageWell partnership after an initial virtual-care pilot connected more than 400 underserved New Yorkers with physician-led care.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

NY Telehealth Extension Advances Rocket Doctor AI Platform

  ()
Rocket Doctor AI extends its New York telehealth engagement through 2029, combining grants and Medicaid to serve underserved patients while scaling its AI platform amid strong digital health market growth.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing

  ()
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Smith & Nephew Expands Wound Care Portfolio in $22B Market

  ()
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Healthcare Platform Clears Major Security Milestone After Independent Audit

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) said its wholly owned Rocket Doctor platform achieved SOC 2 Type I compliance following an independent third-party audit of its security, privacy, and operational controls.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Digital Health Platform Achieves SOC 2 Milestone in Booming Sector

  ()
Rocket Doctor AI reaches SOC 2 Type I compliance, strengthening its enterprise position as the digital health market expands rapidly with rising AI adoption.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Cleantech Co. Relaunches Pet Brand Under Its Own Control

  ()
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

Pet Odor Market Ignites BioLargo Consumer Comeback

  ()
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

Showing Results: 1 to 25 of 53 Next